HD-OPM Archive
Topics › LDL, ApoB & lipid panel

Louis rebuts Shawn Baker's claims about an observational UK Biobank HDL study

Louis Nervegna · Oct 28, 2026 · ♥ 7 reactions · 0 comments · original Facebook post
LDL, ApoB & lipid panelMyths, misinformation & controversies
AI summary & key facts

Louis says an influencer's post misstates a UK Biobank study: it is an observational analysis associating higher HDL with lower ASCVD risk at any given LDL/ApoB, which dozens of earlier studies already showed. He links his own post on what the paper actually says.

Virtually none of what he says in this post is actually in the study that he cites. He doesn’t even get the title of the study right.

This is pretty typical for Shawn Baker. He just makes things up.

Here is the actual journal paper:

Paper · Eur J Prev Cardiol · 2026Interplay of HDL cholesterol and apoB and the risk of incident atherosclerotic cardiovascular disease in UK Biobank.Conclusion: High HDL-C is associated with lower ASCVD risk, independent of apoB, and it attenuates the effect of high apoB on ASCVD risk. These findings suggest HDL-C's role in primary ASCVD prevention warrants re-evaluation. However, findings from an observational study, such as this, do not establish causation.academic.oup.com

You can read it yourself. It is an observational study using UK Biobank data that associates higher HDL with lower risk, at any given level of LDL/ApoB. That is all. This is hardly a new finding. Dozens of previous observational studies have shown this association.

I just did a post on this study in the group. Here is what it actually says, minus all the nonsense from Shawn Baker: ↪ High HDL tracks with lower risk in UK Biobank, but HDL-raising drugs have failed.


#shawnbakerHD #cholesteroldeniersHD #influencersHD #carnivoreHD

Research cited

← newer: Oatmeal has a low glycemic index and lower insulin index thaolder: High HDL tracks with lower risk in UK Biobank, but HDL-raisi →